Abstract
Though recommended by the practice parameters, to date, there is no standardized protocol for dose adjustment following interruption of subcutaneous immunotherapy (SCIT). Following the COVID19 pandemic, immunotherapy was stopped for all our patients (n=664) for nearly 3 months. In this study we describe the development and implementation of a novel dose adjustment protocol.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
